Approximately 45 million people rely on Lilly’s medicines, but many people face barriers to access our innovative therapies. Lilly will continue to find new ways to improve patient access and affordability because we want people to get the medicines they need, regardless of income or geography.
U.S. Transparency & Affordability
In the U.S., Lilly sets a list price for our medicines. To enable patient access, Lilly pays rebates and other discounts to payers and other supply chain entities. These rebates and discounts continued to rise in 2020. The final amount that Lilly receives after paying rebates, discounts and fees is the net amount realized, sometimes called the “net price.” Lilly’s average net price decreased approximately 5% in 2020, the third straight year of decline, even as overall health care prices increased by nearly 2%.
Lilly is committed to reducing out-of-pockets costs for patients, but too often the rebates and discounts we pay into the U.S. health care system don’t reach patients, causing them to incur substantial out-of-pocket costs. For this reason, Lilly launched new programs over the past year so that anyone using Lilly insulin – regardless of their insurance status – is now eligible to buy their monthly prescription for $35.*
*Seniors must enroll in a plan participating in the Part D Senior Savings Model.
Access and Affordability: By the Numbers
$1.2B
value of Lilly medicines provided to patients through the independent Lilly Cares Foundation
$0
out-of-pocket cost for Lilly’s Covid-19 antibody for U.S. patients
2M
people helped each year by patient support programs for Lilly medicines
Access and Affordability Highlights
Lilly Cautionary Statement Regarding Forward-Looking Statements
This document contains forward-looking statements that are based on management’s current expectations, but actual results may differ materially due to various factors. The company’s operations, results, business, goals and strategy may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes or developments in laws and regulations, including health care reform.
For additional information about the factors that affect the company’s business, please see the company’s latest Forms 10-K, 10-Q, and any 8-Ks filed with the Securities and Exchange Commission. The company undertakes no duty to update forward-looking statements except as required by applicable law.
Find more detail on Lilly’s environmental, social and governance priorities, strategies and operations.